Insys Therapeutics, Inc. (NASDAQ:INSY) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01 Entry into a Material Definitive Agreement.

Voting Trust Agreement

Effective as of February 27, 2018, Insys Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a voting trust agreement (the “Voting Trust Agreement”) by and among the Company, Dr. John N. Kapoor (“Dr. Kapoor”), Bessemer Trust Company of Delaware, N.A., as the initial trustee thereunder (the “Trustee”) and certain other specified beneficiaries (the “Beneficiaries”), to which the parties have established a voting trust (within the meaning of Section 218(a) of the Delaware General Corporation Law) (the “Voting Trust”).

During the term of the Voting Trust, the shares of the Company’s common stock, par value $0.01 per share, beneficially owned by Dr. Kapoor and the Beneficiaries, including any such shares acquired subsequent to the effective date of the Voting Trust (the “Kapoor Shares”) shall be deposited with the Trustee and, except under certain limited circumstances, Dr. Kapoor (and the Beneficiaries) will not have control over voting decisions put before the stockholders of the Company.As of the effective date of the Voting Trust Agreement, the Kapoor Shares subject to the Voting Trust totaled 42,536,080 and represented approximately 59% of the outstanding shares of common stock of the Company.In addition, the trustee of Dr. Kapoor’s Children’s Trusts, which trusts hold approximately 4.5 million shares of the Company’s common stock, has executed an irrevocable proxy whereby the shares held by the Children’s Trusts will be voted in the same proportion that the Kapoor Shares are voted.

Until the Voting Trust Agreement is terminated, all Kapoor Shares subject to the Voting Trust shall generally be voted on any matter by the Trustee as directed by a voting committee (the “Voting Committee”) whose members meet certain independence standards with respect to Dr. Kapoor.More specifically, the initial Voting Committee shall consist of: (i) one individual who is an employee or agent of the Trustee; (ii) one member of the Board of the Company who meets specified independence standards; and (iii) three additional individuals who are independent from Dr. Kapoor and the Company.

If at any time the Kapoor Shares subject to the Voting Trust represent less than 40% of the outstanding shares of common stock of the Company, such Kapoor Shares shall be voted on any matter by the Trustee in the same proportion that the shares of the Company’s common stock that are not subject to the Voting Trust are voted on such matter.Finally, at any time during the term of the Voting Trust, with respect to a specified set of extraordinary matter, such as a change of control, Dr. Kapoor and the Beneficiaries shall also be entitled to direct the Trustee to vote “against” such matter.

The Voting Trust Agreement shall continue in effect until terminated upon the earliest to occur of certain specified events, including (i) the Voting Trust ceasing to hold any Kapoor Shares, (ii) the mutual agreement of the Company and Dr. Kapoor and (iii) upon written notice of termination by Dr. Kapoor; provided that, such notice by Dr. Kapoor may not be given unless all criminal charges, civil actions and any corporate integrity or similar agreement to which the Company is a party in connection with the current indictment against Dr. Kapoor have been fully and finally resolved or otherwise expired, as applicable.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the complete terms of the Voting Trust, a copy of which is filed as Exhibit 10.1 hereto, which are incorporated herein by reference.

Registration Rights Agreement

In connection with the establishment of the Voting Trust, the Company entered into a Registration Rights Agreement dated as of February 28, 2018 (the “Registration Rights Agreement”), among the Company, Dr. Kapoor and the Beneficiaries.The Registration Rights Agreement has granted certain customary registration rights to Dr. Kapoor and the Beneficiaries and certain of their assignees (collectively, the “Shareholders”) with respect to shares of the Company’s common stock (the “registrable securities”).Such registration rights include the ability of the Shareholders to request that the Company file a shelf registration statement for the benefit of the Shareholders and provide customary piggyback registration rights for the Shareholders.These registration rights will terminate when the registrable securities cease to be registrable securities under the terms of the Registration Rights Agreement.The Registration Rights Agreement also includes certain standstill provisions applicable to the Shareholders which provide, among other things, that the Shareholders shall not facilitate or encourage any third party to effect or seek certain extraordinary transactions with respect to the Company (including any change of control transactions).

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the complete terms of the Registration Rights Agreement, a copy of which is filed as Exhibit 10.2 hereto, which are incorporated herein by reference.

(d) Exhibits.

Insys Therapeutics, Inc. Exhibit
EX-10.1 2 insy-ex101_7.htm EX-10.1 insy-ex101_7.htm Exhibit 10.1   EXECUTED VERSION               VOTING TRUST AGREEMENT RELATING TO SHARES OF INSYS THERAPEUTICS,…
To view the full exhibit click here

About Insys Therapeutics, Inc. (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.